Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on Kura Oncology (KURA – Research Report), retaining the price target of $28.00.
Reni Benjamin has given his Buy rating due to a combination of factors, primarily centered around Kura Oncology’s recent submission of the NDA for zifto in relapsed/refractory NPM1-m AML. This milestone underscores the company’s capability to execute its strategic plans and positions it for potential revenue generation by late 2025 or early 2026. The anticipated approval of zifto, which has received Breakthrough Therapy Designation, is expected by the end of the year, enhancing the attractiveness of Kura’s stock.
Furthermore, Kura’s robust cash position and the fully funded zifto franchise in first-line AML, coupled with positive top-line results from the KOMET-001 trial, contribute to the optimistic outlook. The company’s strategic partnership with Kyowa, which includes significant funding and a profit-sharing agreement, further strengthens its financial and operational prospects. These elements collectively suggest that Kura Oncology represents a compelling investment opportunity, particularly given its current enterprise value.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $24.00 price target.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KURA in relation to earlier this year.